Otros idiomas Gritstone bio, Inc.

Acciones

GRTS

US39868T1051

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,8737 ^USD	+9,21 %		+7,48 %	-57,17 %

29/04	Gritstone Bio, Inc. anuncia cambios en su Consejo de Administración	CI
15/04	Nature Medicine publica los resultados provisionales del estudio de fase 1/2 de Gritstone Bio sobre la plataforma de vacuna neoantígena "lista para usar" (SLATE)	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024	30/04
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors	29/04
Gritstone Bio, Inc. Announces Board Changes	29/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	20/04
Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of 'Off-the-Shelf' Neoantigen Vaccine Platform	16/04
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)	15/04
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	15/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	12/04
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences	08/04
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024	08/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	05/04
Top Midday Decliners	02/04
Gritstone bio Prices $32.5 Million Public Offering of Stock, Warrants	02/04
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering	02/04
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall	01/04
Gritstone Bio Starts Public Offering; Shares Drop After-Hours	01/04
Gritstone bio Announces Proposed Public Offering	01/04
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)	01/04
Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite	01/04
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS	19/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Gritstone bio, Inc.

Acciones

GRTS

US39868T1051

Otros idiomas

Filtros